In situ adenovirus vaccination engages T effector cells against cancer
- 24 June 2009
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 27 (31), 4225-4239
- https://doi.org/10.1016/j.vaccine.2009.03.074
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Oncolytic viruses: a novel form of immunotherapyExpert Review of Anticancer Therapy, 2008
- TGF-β: A Master of All T Cell TradesCell, 2008
- Adenovirus E3/19K Promotes Evasion of NK Cell Recognition by Intracellular Sequestration of the NKG2D Ligands Major Histocompatibility Complex Class I Chain-Related Proteins A and BJournal of Virology, 2008
- Subversion of CtBP1-controlled macropinocytosis by human adenovirus serotype 3The EMBO Journal, 2008
- Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and ImmunotherapyJournal of Virology, 2008
- Adenovirus-Platelet Interaction in Blood Causes Virus Sequestration to the Reticuloendothelial System of the LiverJournal of Virology, 2007
- Innate Immune Response to Adenoviral Vectors Is Mediated by both Toll-Like Receptor-Dependent and -Independent PathwaysJournal of Virology, 2007
- Tumor Cells Expressing Anti-CD137 scFv Induce a Tumor-Destructive EnvironmentCancer Research, 2007
- The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designNature Reviews Immunology, 2006
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002